Dr. Reddy's to release Q3 FY18 results on January 25, 2018
January 16 2018 - 3:57AM
Business Wire
Earnings call slated for January 25, 6:30 PM
IST / 8:00 AM EST
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
will announce results for the Third Quarter ended December 31, 2017
on Thursday, January 25, 2018 after the Board Meeting. The results
will be available on the Company’s website www.drreddys.com.
Summary of Events
Event Date and Time
Medium Release of financial results
January 25th, after the Board Meeting
Email, Media, Company website, Business wire Earnings Call
January 25th, 6:30 PM IST / 8:00 AM EST
Hosted by the Company
(Details below)
Webcast of Earnings Call January 25th, 6:30 PM
IST / 8:00 AM EST through January 29th
URL available on Company’s website,
www.drreddys.com
Transcript of the Earnings call Will be
available on the Company’s website
URL available on Company’s website,
www.drreddys.com
Press meet presentation Will be available on
the Company’s website
URL available on Company’s website,
www.drreddys.com
Earnings Call
Following the release, the management of the Company will host
an earnings call to discuss the Company’s financial performance.
(Dial In and other details given below)
Audio Webcast
The audio webcast of the earnings call will be available to all
interested parties at www.drreddys.com. Please visit the web site
at least fifteen minutes ahead of the scheduled start time to
register and to download and install any necessary audio software.
Participants in the webcast can listen to the proceedings, but will
not be able to ask questions. The replay will be available 2 hours
after the earnings call, through January 29th, 2018. For play back
dial in phone No: 022 3065 2322, and ID: 375#.
Conference Dial-In Numbers Primary Number:
+91 22 3960 0616
The numbers listed above are universally accessible from all
networks and all countries. Local Access Number:
Accessible from all major carriers except
BSNL/MTNL.3940 3977Available in Ahmedabad, Bangalore,
Chandigarh, Chennai, NCR (Delhi, Gurgaon, Noida), Hyderabad,
Jaipur, Kochi, Kolkata, Lucknow, PuneAccessible from all
carriers.
International Toll Free Number:
USA: 1 866 746 2133UK: 0 808 101
1573Singapore: 800 101 2045Hong Kong: 800 964
448
No password/pin number is necessary to dial in to any of the
other calls. As participation in the call is limited, early
registration is encouraged. The operator will provide instructions
on asking questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr Reddy’s operates in
markets across the globe. Our Major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180116005853/en/
Dr. Reddy's LaboratoriesINVESTOR RELATIONSSAUNAK SAVLAPh:
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN
PRINTERPh: +91-40- 49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024